Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Detection and treatment of cancer

A technology of biological samples and antibodies, applied in the field of cancer detection and/or treatment, which can solve the problems of disappearance of staining and low availability of extracellular proteins

Inactive Publication Date: 2004-06-09
里卡尔多 J 莫罗
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, it remains unclear whether AFP and SA uptake is a cell-dependent phenomenon, or whether the extracellular protein is less available due to closure of the brain-blood barrier or low concentrations of circulating AFP at the end of fetal life causing the loss of color

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Detection and treatment of cancer
  • Detection and treatment of cancer
  • Detection and treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] In this example, 22 serum samples from non-cancer patients and 17 samples from cancer patients were tested for AFP receptor concentrations by enzyme immunoassay (EIA) using the following technique: in phosphate-buffered saline (PBS) (0.05MPO 4Serum samples from the above groups diluted 1 / 16384 in , 0.15M NaCl, pH 7.5) were coated on EIA 96-well plates for 1 hour to overnight. In a similar manner wells were coated with pleural effusion from a patient with lung metastases from breast cancer at a dilution of 1 / 256. Due to its availability in large quantities, this material, called P89, was used as a standard, which allowed P89 to be used as the same standard to compare all samples with all other samples in all experiments. After washing 3 times with PBS, non-specific binding sites were blocked with 1% ovalbumin or gelatin in PBS for 1 hour. After washing 3 times, 100 μl of ascitic fluid (as described in [Moro, R., Tamaoki, T., Wegmann, T.G., Longenecker.B.M., and Ladera...

Embodiment 2

[0101] In another embodiment, an appropriate plastic or glass substrate (EIA plate or test tube) is coated with AFP receptor monoclonal antibody (Mab) at an appropriate concentration. After washing away excess Mab, the substrate is blocked with an irrelevant protein or amino acid to prevent non-specific binding, and the coated substrate is incubated with an appropriate sample dilution of the patient's bodily fluids (serum, saliva, urine, etc.) After a period of time, after washing to remove unbound sample material, a secondary antibody of the polyclonal type (polyclonal antibody produced by immunizing an animal and using its serum as a reactive antibody source, as opposed to Mab, which is obtained by culturing produced by individual cloning or transplantation of immortal splenocytes into a suitable host), this antibody can be coupled to a suitable marker or enzyme for color development, or, by adding an anti-secondary antibody labeled with said marker or enzyme The secondary a...

Embodiment 3

[0103] Same as Example 2 but using two different polyclonal antibodies instead of monoclonal antibody and antibody as primary and secondary antibodies respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

A method for detecting cancer in a patient. The method comprises the steps of introducing labeled antibodies or labeled AFP to a biological sample of the patient so the labeled antibodies or labeled AFP will react with the AFP receptor binding sites in the biological sample. Next there is the step of identifying AFP receptor binding sites in the biological material which are reacted with the labeled antibodies or labeled AFP to determine the presence of cancer. Preferably, before the introducing step, there is the step of obtaining a biological sample from a body of a patient. A method for treating cancer cells in a patient. The method comprises the steps of introducing AFP receptor antibodies to cancer cells in the patient. Then there is the step of reacting the AFP receptor antibodies with the AFP receptor of the cancer cells to inhibit growth of the cancer cells or kill the cancer cells. A method for monitoring a patient. The method comprises the steps of treating the patient for cancer. Then there is the step of testing the patient at predetermined intervals after the treatment for AFP receptor site levels. A method for treating a patient. The method comprises the steps of testing the patient for AFP receptor. Then there is the step of introducing AFP receptor antibodies or AFP into the patient to react with cancer cells in the patient if the testing indicates AFP receptors are in the patient. A method for treating cancer cells in a patient. The method comprises the steps of introducing modified AFP to cancer cells in the patient. Then there is the step of reacting the modified AFP with the AFP receptor of the cancer cells to inhibit growth of the cancer cells or kill the cancer cells.

Description

[0001] This application is a divisional application of an invention patent application with an application date of September 18, 1995, an application number of 95195125.4, and an invention title of "Detection and Treatment of Cancer". technical field [0002] The present invention relates to the detection and / or treatment of cancer. In more detail, the present invention uses the presence of AFP receptors as a basis to detect cancer in a patient or to contain or eliminate cancer. Background technique [0003] Twenty years ago, Abelev et al. reported the presence of the first carcinoembryonic antigen, alpha-fetoprotein (AFP) [Abelev, G.I., Perova, S.D., Khramkova, N.I., Postnikova, Z.A. and Irlin, I.S. "Transplantation" 1, 174 (1963)], although it is the main circulating protein in the fetus, it almost disappeared after birth, and its normal adult serum concentration is less than 50ng / ml [Ruoslahti, E. and Seppals.M ., International Journal of Cancer 8, 374 (1971)]. However,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P35/00G01N33/574G01N33/68
CPCA61K47/48569Y10S977/92G01N33/57476A61K47/48384A61K47/48438A61K2039/505A61K51/1045C07K16/30A61K47/6817A61K47/6851A61P35/00G01N33/574A61K47/50G01N33/577
Inventor 里卡尔多·J·莫罗
Owner 里卡尔多 J 莫罗
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com